mitoxantrone + prednisone

The combination of mitoxantrone and prednisone is a treatment regimen used primarily for hormone-resistant (also called hormone-refractory) metastatic prostate cancer. This combination has been studied in randomized clinical trials and has shown significant benefits for pain palliation and quality of life improvements compared to prednisone alone. ## Efficacy and Clinical Evidence Mitoxantrone plus prednisone has demonstrated superior outcomes compared to prednisone monotherapy in several key areas: - **Pain Reduction**: In a Canadian randomized trial with 161 patients, palliative response was observed in 29% of patients receiving the combination therapy versus 12% with prednisone alone[2][3]. The duration of palliation was significantly longer with the combination (median 43 weeks vs 18 weeks)[2][3]. - **Quality of Life**: Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several health-related quality of life domains and symptoms compared to prednisone alone[1]. After 6 weeks, patients on the combination therapy showed significant improvements in global quality of life, four functioning domains, and nine symptoms[1]. - **Cross-over Benefit**: Patients who initially received prednisone alone and did not respond could benefit from adding mitoxantrone later, with 11 of 50 such patients showing response after the addition[2][3]. ## Administration The treatment regimen typically consists of: - Mitoxantrone given intravenously every 3 weeks (one cycle) - Prednisone administered daily (either 10 mg once daily or 5 mg twice daily)[4] ## Side Effects The combination therapy is generally well-tolerated with some notable side effects: - **Mitoxantrone-related**: Potential cardiac toxicity (observed in 5 of 130 patients who received mitoxantrone in clinical trials)[2][3], loss of appetite, weight loss, tiredness, and hair thinning (rarely complete hair loss)[4]. - **Prednisone-related**: Heartburn, nausea, increased risk of stomach problems such as bleeding ulcers[4]. ## Current Status While newer treatments have emerged for metastatic castration-resistant prostate cancer, the mitoxantrone plus prednisone combination remains a palliative option that can provide meaningful symptom relief for some patients, particularly for pain management and quality of life improvement.